Rheumatoid arthritis associated interstitial lung disease: A review;La artritis reumatoide asociada a la enfermedad intersticial pulmonar: Una revisión

Medicina (Argentina)

Volumn 74, Issue 2, 2014, Pages 158-165

  Assayag, Deborah ^a   Lee, Joyce S ^a   King, Talmadge E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interstitial lung disease; Pathogenesis; Rheumatoid arthritis; Risk factors

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; BLEOMYCIN; CIGARETTE SMOKE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN; GOLD; HEAT SHOCK PROTEIN 90; HLA DRB1 ANTIGEN; KREBS VON DEN LUNGEN 6 PROTEIN; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BRONCHIECTASIS; BRONCHOSCOPY; CD4+ T LYMPHOCYTE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DESQUAMATIVE INTERSTITIAL PNEUMONIA; DIFFUSE ALVEOLAR DAMAGE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FIBROSING ALVEOLITIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GROUPS BY AGE; HISTOPATHOLOGY; HONEYCOMBING; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MASCULINITY; MORTALITY; NONHUMAN; ORGANIZING PNEUMONIA; PATHOGENESIS; PHENOTYPE; PREVALENCE; PROGNOSIS; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RISK FACTOR; SMOKING; SPUTUM; SURVIVAL; THORAX PAIN; THORAX RADIOGRAPHY; WHEEZING; ARTHRITIS, RHEUMATOID; COMPLICATION; LUNG DISEASES, INTERSTITIAL;

ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; RISK FACTORS;

EID: 84907733232     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. McInnes IB, G. Schett, The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16: 513-37.
3. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269-81.
4. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007. Arthritis & Rheumatism 2010; 62: 1576-82.
5. Barragán-Martínez C, Amaya-Amaya J, Pineda-Tamayo R, et al. Gender differences in Latin-American patients with rheumatoid arthritis. Gender Medicine 2012; 9: 490-510. e5.
6. Jawaheer D, Lum RF, Gregersen PK, Criswell LA. Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheumatism 2006; 54: 3087-94.
7. Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis?: Results from the Nurses' Health Study. Arthritis Rheumatism 2004; 50: 3458-67.
8. Tengstrand B, Carlström K, Hafström I. Bioavailable testosterone in men with rheumatoid arthritis-high frequency of hypogonadism. Rheumatology 2002; 41: 285-9.
9. Hoovestol R. Mikuls TR. Environmental exposures and rheumatoid arthritis risk. Curr Rheumatol Rep 2011; 13: 431-9.
10. Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4, 000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77: 1044-60.
11. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44: 1336-40.
12. Deighton CM, Walker DJ, Griffiths ID, Roberts DF, et al. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989; 36: 178-82.
13. Sullivan PW, Ghushchyan V, Huang XY, Globe DR. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010; 37: 544-9.
14. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-7.
15. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998; 19: 667-85.
16. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
17. Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore) 2013; 92: 92-7.
18. Norton S, Koduri G, Nikiphorou E, Dixey J, Williams P, Young A. A study of baseline prevalence and cumulative incidence of co-morbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology 2013; 52: 99-110.
19. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosingalveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-627.
20. Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis: Prospective study in 75 patients. Joint Bone Spine 2005; 72: 41-7.
21. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatology Intern 2012; 32: 669-73.
22. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: 528-35.
23. Gochuico BR, Avila NA, Chow CK, et al. PRogressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Int Med 2008; 168: 159-66.
24. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheumatism 2010; 62: 1583-91.
25. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Resp Critical Care Med 2011; 183: 372-8.
26. Furukawa H, Oka S, Shimada K, et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS One 2012; 7: e33133.
27. Johnson C. Exploration of the MUC5B polymorphism frequency in rheumatoid arthritis interstitial lung disease. Am J Respir Crit Care Med 2013; 187: A5982.
28. Sakaguchi, S. SKG mice, A new genetic model of rheumatoid arthritis. Arthritis Res Ther 2003; 5(Suppl 3): 10.
29. Keith RC, Powers JL, Redente EF, et al. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice. Exp Lung Res 2012; 38: 55-66.
30. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with Co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011; 38: 979-82.
31. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012; 106: 1591-9.
32. Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 2010; 49: 1483-9.
33. Bergström U, Jacobsson LT, Nilsson JÅ, Berglund G, Turesson C. Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology 2011; 50: 2005-13.
34. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease: Determinants of radiographic and physiologic abnormalities. Arthritis Rheumatism 1996; 39: 1711-9.
35. Giles JT, Danoff SK, Sokolove J, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2013 (Epub date 2013/05/30).
36. Picchianti Diamanti A, Germano V, Bizzi E, Laganà B, Migliore A. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulm Med 2011; 2011/931342.
37. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheumatic Dis 2010; 69: 1086-91.
38. Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med 2011; 2011: 872120.
39. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-27.
40. Solomon JJ, Ryu JH, Tazelaar HD, et al., Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013; 107: 1247-52.
41. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Euro Respir J 2010; 35: 1322-28.
42. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol, 2004; 14: 272-80.
43. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Euro Respir J 2011; 37: 1411-7.
44. Skare TL, Nakano I, Escuissiato DL, Batistetti R, Rodrigues Tde O, Silva MB. Pulmonary changes on high-resolution computed tomography of patients with rheumatoid arthritis and their association with clinical, demographic, serological and therapeutic variables. Rev Bras Reumatol 2011; 51: 325-30, 336-7.
45. Pappas DA, Giles JT, Connors G, Lechtzin N, Bathon JM, Danoff SK. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther 2010; 12: R104.
46. Chen J, Shi Y, Wang X, Huang H, Ascherman D. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol 2013; 2013: 406927.
47. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related Lung Diseases: CT Findings1. Radiology 2004; 232: 81-91.
48. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005; 25: 429-35.
49. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
50. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014; 270: 583-8.
51. Perez T, Farre JM, Gosset P, et al. Subclinical alveolar inflammation in rheumatoid arthritis: superoxide anion, neutrophil chemotactic activity and fibronectin generation by alveolar macrophages. Euro Respir J 1989; 2: 7-13.
52. Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004; 98: 1131-7.
53. Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27: 1164-70.
54. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 511-3.
55. Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinated Hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatism 2013; 65: 869-79.
56. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin 2012; 8: 68-71.
57. Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009; 48: 1069-72.
58. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheumatism 2011; 41: 256-64.
59. Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiology Drug Safety 2013; 22: 394-402.
60. Young A, Koduri G, Batley M, et al. Early rheumatoid arthritis study group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007; 46: 350-7.
61. Lee H, Choe JY, Kim SK, et al., Important prognostic factor in rheumatoid arthritis patients with interstitial lung disease is not usual interstitial pneumonia pattern but interstitial lung disease extent on chest high-resolution computed tomography. Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC United States 2012; 64: S528.
62. Song JW, Lee HK, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. SarcoidosisVasc Diffuse Lung Dis 2013; 30: 103-12.
63. Hozumi H, Nakamura Y, Johkoh T, et al., Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 2013; 3: e003132.
64. Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2013; 69: 216-22.
65. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Jr., Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-77.
66. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008; 41: 1074-7.
67. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007; 132: 214-20.